This national consensus, based on evidence and formal expert consensus, aims to optimize the care of patients with advanced HER2-positive and HER2-low breast cancer, improving clinical outcomes and promoting equitable access to innovative therapies. This evidence concerns the gene ERBB2 and breast carcinoma.